Tag Archive for: American Society of Haematology

CellCentric presents early clinical data at ASH

/in

Inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma Inobrodib is an oral drug showing good long-term tolerability at the recommended phase 2 dose as monotherapy Objective responses have been observed in heavily pre-treated relapsed/ refractory multiple myeloma patients Inobrodib is also being evaluated in combination with pomalidomide/ dexamethasone, with clear […]

Read more

CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology

/in

Inobrodib is a pioneering drug targeting twin tumour drivers p300/CBP, providing a new way to treat specific cancers Objective responses have been observed in multiple settings, including as monotherapy in relapsed refractory multiple myeloma ASH is the annual flagship scientific and clinical haematology meeting which is taking place in New Orleans on 9-13 December 2022 […]

Read more